腹主动脉瘤腔内修复术后瘤囊缩小的影响因素:系统评价与荟萃分析
该系统评价与荟萃分析纳入24项研究共14,754例EVAR患者,平均随访24个月,合并瘤囊缩小比例为47%。随机效应模型显示肾功能不全及I型、II型内漏阻碍瘤囊缩小,而高胆固醇血症和吸烟与瘤囊缩小正相关。
要点
- EVAR术后平均随访24个月瘤囊缩小合并比例为47%。
- 肾功能不全及I型、II型内漏是瘤囊缩小的阻碍因素。
- 高胆固醇血症和吸烟与瘤囊缩小呈正相关。
核心结论
- 多种合并症及术后因素与EVAR术后瘤囊缩小相关,有助于理解瘤囊缩小过程。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase和Cochrane Library数据库,纳入24项研究共14,754例EVAR患者(平均年龄73.4岁,76%为男性),采用随机效应模型合并效应量。
主要发现
- 平均随访24个月,瘤囊缩小合并比例为47%。
- 肾功能不全(OR 0.74,95%CI 0.57-0.96)、I型内漏(OR 0.17,95%CI 0.08-0.39)、II型内漏(OR 0.21,95%CI 0.14-0.33)及I+II型内漏(OR 0.32,95%CI 0.22-0.47)阻碍瘤囊缩小。
- 高胆固醇血症(OR 1.24,95%CI 1.02-1.51)和吸烟(OR 1.32,95%CI 1.17-1.49)对瘤囊缩小有显著正向影响。
- 他汀治疗与瘤囊缩小存在关联趋势(OR 4.07,95%CI 1.02-16.32),冠心病(OR 0.84,95%CI 0.70-1.01)、糖尿病(OR 0.79,95%CI 0.60-1.04)及瘤囊血栓(OR 0.88,95%CI 0.77-1.01)呈接近显著的负向影响。
临床怎么用
- EVAR术后随访中应关注肾功能不全及内漏对瘤囊缩小的不利影响。
- 高胆固醇血症和吸烟状态可能提示瘤囊缩小概率较高,但需结合其他因素综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sac shrinkage is considered a reliable surrogate marker of success after endovascular aneurysm repair (EVAR). Whereas sac shrinkage is the best expected outcome, predictive factors of sac shrinkage remain unclear. The aim of this study was to identify the role of preoperative and postoperative influencing factors of sac reduction after EVAR. METHODS: Online searches across MEDLINE, Embase, and Cochrane Library medical databases were simultaneously performed. Study effects were pooled using a random-effects model, and forest plots were generated for every potential influencing factor. RESULTS: A total of 24 studies with 14,754 patients were included (mean age, 73.4 years; 76% male). At a mean follow-up of 24 months, the pooled shrinkage proportion was 47%. Random-effects meta-analysis revealed that renal impairment (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.57-0.96), type I endoleaks (OR, 0.17; 95% CI, 0.08-0.39), type II endoleaks (OR, 0.21; 95% CI, 0.14-0.33), and combined type I and type II endoleaks (OR, 0.32; 95% CI, 0.22-0.47) were found to prevent sac shrinkage, whereas hypercholesterolemia (OR, 1.24; 95% CI, 1.02-1.51) and smoking (OR, 1.32; 95% CI, 1.17-1.49) have a significant positive impact on sac shrinkage. In addition, there was a trend toward the association between shrinkage and statin therapy (OR, 4.07; 95% CI, 1.02-16.32) and nearly significant negative impacts of coronary artery disease (OR, 0.84; 95% CI, 0.70-1.01), diabetes (OR, 0.79; 95% CI, 0.60-1.04), and sac thrombus (OR, 0.88; 95% CI, 0.77-1.01) on sac shrinkage. CONCLUSIONS: In this large meta-analysis of patients undergoing EVAR, we found that several comorbidity and postoperative factors were associated with postoperative sac shrinkage. These findings may contribute to a better understanding of the shrinkage process of patients undergoing EVAR.
引用
- Lalys F, Daoudal A, Gindre J, et al. Influencing factors of sac shrinkage after endovascular aneurysm repair. J Vasc Surg. 2017. PMID: 28359714. doi:10.1016/j.jvs.2016.12.131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。